Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
- PDF / 719,690 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 63 Downloads / 233 Views
BRIEF RESEARCH ARTICLE
Neutrophil‑to‑lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy G. L. Banna1,2 · R. Di Quattro3 · L. Malatino3 · G. Fornarini4 · A. Addeo5 · M. Maruzzo6 · V. Urzia3 · F. Rundo7 · H. Lipari1 · U. De Giorgi8 · U. Basso6 Received: 15 January 2020 / Accepted: 12 March 2020 © Federación de Sociedades Españolas de Oncología (FESEO) 2020
Abstract Purpose To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs). Methods/Patients We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients. Results NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p
Data Loading...
